Last Update 17 Jun 26

CGEN: Bullish Views Persist As Immuno Oncology Pipeline Progress Supports Upside

Analysts have reduced their price target on Compugen stock to $5, down $8 from the prior $13 target, citing updated assumptions for discount rate, profit margin and future P/E, while maintaining a constructive fundamental view on the company.

Analyst Commentary

Recent research on Compugen stock reflects a mix of constructive views on the company and more cautious adjustments to valuation, giving you a clearer sense of how professionals are framing risk and reward.

Bullish Takeaways

Bullish analysts maintain positive ratings on Compugen despite the lower price target, indicating continued confidence in the company’s core fundamentals and long term potential.
The revised US$5 target still reflects an expectation that Compugen can create value if it executes on its plans, even with more conservative assumptions for discount rate, profit margin and future P/E.
Supportive commentary points to a constructive view on the company’s ability to progress its business, which underpins the decision to keep an Outperform style stance rather than move to a neutral rating.
The continued coverage and fresh initiation with a bullish view suggest that Compugen remains on the radar for analysts looking for companies where improved execution could eventually support higher valuations.

Bearish Takeaways

The cut in the price target from US$13 to US$5 signals that bearish analysts are building in more conservative outcomes for Compugen, particularly around profitability and future valuation multiples.
Lower assumed profit margins indicate concern that earnings may be pressured relative to prior expectations, which directly weighs on what analysts are willing to pay for the stock.
Adjustments to the future P/E assumption suggest that analysts see a higher risk that Compugen may not command the same valuation premium that had been previously modeled.
Changes to the discount rate reflect a more cautious stance on risk, which reduces the present value of Compugen’s projected cash flows and constrains upside in target prices.

What’s in the News for Compugen

Compugen plans to present a trial in progress poster on the MAIA ovarian Phase 1 study of COM701, an anti PVRIG antibody, at the ESMO Gynaecological Cancers Congress 2026 in Copenhagen, Denmark, from June 17 to June 19, 2026. The poster session is scheduled for June 18, 2026, from 12:45 to 13:30 CEST. (Source: Company product related announcement)
The MAIA ovarian study (NCT06888921) is described as an adaptive platform clinical trial evaluating COM701 as maintenance treatment in relapsed platinum sensitive ovarian cancer, with COM701 used as a single agent in this setting. (Source: Company product related announcement)
Compugen highlights a clinical stage immuno oncology pipeline of four programs: COM701, COM902, rilvegostomig and GS 0321, covering monotherapy and combination approaches across solid tumor indications. (Source: Company product related announcement)
Rilvegostomig, a PD 1/TIGIT bispecific antibody with a TIGIT component derived from the COM902 program, is being developed by AstraZeneca under an exclusive license agreement and is under evaluation in multiple Phase 3, Phase 2 and Phase 1 trials. (Source: Company product related announcement)
GS 0321, previously COM503, is licensed to Gilead as a high affinity antibody that blocks the interaction between IL 18 binding protein and IL 18 and is currently in a Phase 1 clinical trial conducted by Compugen, alongside additional early stage immuno oncology research programs. (Source: Company product related announcement)

Valuation Changes for Compugen

Fair Value: Held steady at $4.6, with no change in the modeled intrinsic value per share.
Discount Rate: Edged down slightly from 8.65% to 8.62%, implying a marginally lower required rate of return in the model.
Revenue Growth: Remains modeled as a 30.93% decline, with no adjustment to the forecast growth rate.
Net Profit Margin: Trimmed slightly from 19.04% to 18.98%, reflecting a modestly more cautious view on future profitability for Compugen.
Future P/E: Ticked up slightly from 125.56x to 125.81x, indicating a marginally higher valuation multiple assumed in the updated analysis.

4 views

Key Takeaways

Partnerships with top pharmaceutical firms and a focus on innovative immunotherapies position Compugen to benefit from industry trends and expand its market reach.
Advancing clinical trials and favorable regulatory momentum may enable faster drug approvals, potentially driving earlier and more stable revenue growth.
Heavy dependence on uncertain clinical milestones, external funding, and partnerships, amid strong competition and regulatory headwinds, threatens Compugen's profitability and future market position.

Catalysts

About Compugen

A clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe.What are the underlying business or industry changes driving this perspective?

Compugen is advancing its AI/ML-powered computational target discovery platform (Unigen), positioning it to capitalize on the rising importance of precision medicine and biomarker-driven drug development in oncology, which could support higher future revenue as targeted and differentiated therapies are increasingly sought.
Strategic partnerships with leading pharmaceutical companies such as AstraZeneca and Gilead provide milestones and potential royalties tied to the success of their co-developed assets, potentially driving meaningful top-line growth and improving future margin stability as partnered drugs advance through clinical trials and toward commercialization.
The pipeline's focus on novel immune checkpoint inhibitors (e.g., COM701, COM902) and differentiated mechanisms aligns with the growing demand for innovative immunotherapies driven by global increases in cancer incidence and aging populations, directly expanding Compugen's potential addressable market and eventual revenues.
Execution on ongoing clinical trials, especially the COM701 maintenance study in platinum-sensitive ovarian cancer addressing significant unmet medical need, positions the company for potential near
to mid-term value inflections; positive results would de-risk future pipeline development and accelerate revenue from new indications.
Broadening regulatory and industry momentum towards expedited approval pathways and combination immunotherapy regimens increases the likelihood that Compugen's assets could achieve faster market access, which could lead to earlier revenue recognition and improved long-term earnings potential.

Compugen Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Compugen's revenue will decrease by 30.9% annually over the next 3 years.
Analysts are not forecasting that Compugen will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Compugen's profit margin will increase from 48.0% to the average US Biotechs industry of 19.0% in 3 years.
If Compugen's profit margin were to converge on the industry average, you could expect earnings to reach $4.5 million (and earnings per share of $0.05) by about June 2029, down from $34.9 million today.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 126.7x on those 2029 earnings, up from 5.5x today. This future PE is greater than the current PE for the US Biotechs industry at 16.4x.
Analysts expect the number of shares outstanding to grow by 1.09% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 8.62%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

Persistent lack of late-stage or commercial products and reliance on milestone and royalty payments means Compugen continues to record large operating losses and negative net income (as seen with Q2 2025 net loss of $7.3 million); this dependence on external cash inflows and uncertain clinical progress increases risk of future shareholder dilution and challenges to reaching profitability.
Delays or failures in clinical development of lead assets (such as COM701 and COM902), or disappointing interim results in adaptive trials, could severely reduce the company's ability to achieve future milestone revenues and successfully monetize partnerships, directly impacting revenue and cash flow projections.
Growing competition in the immuno-oncology space, including several differentiated programs in both platinum-sensitive and platinum-resistant ovarian cancer as well as TIGIT-targeting therapies, may erode Compugen's market opportunity by limiting best-in-class positioning and reducing potential revenues from existing and future collaborations.
Macroeconomic instability or shifts in biotech investor sentiment (particularly due to negative clinical data, sector downturns, or risk aversion for cash-burning precommercial companies) may raise the cost of capital and make future fundraising more dilutive, harming earnings per share and net margins.
Regulatory or reimbursement pressures-such as potential tightening of approval pathways for immunotherapies, payer reluctance to cover new high-cost therapies, or increasing global healthcare cost-containment-could delay time-to-market, constrain attainable pricing, and limit the overall commercial revenue pool for Compugen's assets.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $4.6 for Compugen based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $6.0, and the most bearish reporting a price target of just $4.0.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $23.9 million, earnings will come to $4.5 million, and it would be trading on a PE ratio of 126.7x, assuming you use a discount rate of 8.6%.
Given the current share price of $2.03, the analyst price target of $4.6 is 55.9% higher. Despite analysts expecting the underlying business to decline, they seem to believe it's more valuable than what the market thinks.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Compugen?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

AI And Immunotherapy Advances Will Define Oncology's Future